Role of the Systemic Immune-Inflammation Index and Systemic Immune-Response Index in the Prediction of Adverse Outcomes in Pregnant Women With Antiphospholipid Syndrome

Abstract

Problem

This study aims to evaluate the role of the systemic immune-inflammation index (SII) and the systemic immune-response index (SIRI) in predicting adverse perinatal outcomes (APO) in pregnant women with antiphospholipid syndrome (APS).

Methods

This is a retrospective case–control study at the tertiary center, between January 2015 and January 2023. The study included APS cases and a low-risk control group. Pregnant women with APS (n = 52) and controls (n = 104) were compared between SII and SIRI values taken in the first trimester (1) and the last month before birth (2). It was examined whether these indexes predicted APO in cases with APS.

Results

In the APS group, SII and SIRI values taken in the first trimester (1) and in the last month before birth (2) were significantly lower than in the control group (p = 0.015, p = 0.023, p = 0.001, p = 0.001, respectively). The small for gestational age (SGA) rate was 30.8% and the stillbirth rate was 11.5% in the APS group (p = 0.017, p = 0.001). The optimum cutoff values for SGA were 584.97 (75% sensitivity, 77.8% specificity), 688.50 (62.5% sensitivity, 62.9% specificity), and 1.02 (56.3% sensitivity, 77.8% specificity) for SII 1, SII 2, and SIRI 1, respectively. The optimum cutoff value for stillbirth was 1.23 for SIRI 2 (83.3% sensitivity, 89.1% specificity, p = 0.004).

Conclusion

Pregnant women with APS had decreased blood indices in the first trimester and the last month before birth compared to the control group. In cases with APS, these indices can predict APOs like SGA and stillbirth.